1. Escalating drug delivery in cancer chemotherapy: A review of concepts and practice —Part 2
2. Cytotoxic drugs: the search for dose response
3. Out of the courtroom and into the clinic.
4. Dose-response in the treatment of breast cancer: a critical review.
5. Folic acid and its reduced counterparts enter cells via two unrelated pathways (Dixon, K. H.; Lanpher, B. C.; Chiu, J.; Kelley, K.; Cowan, K. H.J.Biol. Chem.1994,269, 17). The primary intake route is mediated by the reduced folate carrier, a transport protein that exhibits aKmfor folate near 5 × 10-6M and a strong preference for reduced folates over folic acid. The second path of folate uptake is mediated by a family of membrane receptors termed the folate binding protein (FBP) (Brigle, K. E.; Spinella, M. J.; Westin, E. H.; Goldman, I. D.Biochem. Pharmacol.1994,47, 337. Shen, F.; Ross, J. F.; Wang, X.; Ratnam, M.Biochemistry1994,33, 1209. Leamon, C. P.; Low, P. S.Biochem. J.1993291, 855. Garin-Chesa, P.; Campbell, I.; Saigo, P. E.; Lewis, J. L., Jr.; Old, L. J.; Rettig, W.J. Am. J. Pathol.1993,142, 557). FBP has aKDfor folate that varies from 10-9to 10-11and exhibits a strong preference for folic acid over its reduced counterparts (Low, P. S.Proc. Natl. Acad. Sci.U.S.A.1991,88, 5572).